<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02148198</url>
  </required_header>
  <id_info>
    <org_study_id>AFCRO-041-part 1</org_study_id>
    <nct_id>NCT02148198</nct_id>
  </id_info>
  <brief_title>Effect of NWT-03 on Blood Pressure - Part 1</brief_title>
  <official_title>A Study of Two Parts to Determine the Effect of NWT-03 on Blood Pressure in Healthy Subjects. Part 1: A Dose Ranging, Cross-over Study to Determine the Effect of 1g, 2g &amp; 5gs of NWT-03 Versus Placebo on Blood Pressure in Healthy Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Newtricious R&amp;D BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Newtricious R&amp;D BV</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Part 1 of the study will assess the effect of 1g, 2g and 5g doses of NWT-03 on systolic and&#xD;
      diastolic blood pressure in a cross-over designed study in healthy adults with normal, high&#xD;
      normal and mild hypertension. Based on results from this study, one dose will be selected for&#xD;
      a placebo controlled parallel study assessing a single dose of NWT-03 on systolic and&#xD;
      diastolic blood pressure and endothelial function in a similar population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in average daytime systolic blood pressure at 5 days</measure>
    <time_frame>For both intervention periods: 48h ABPM before baseline visit and 5 days after baseline visit</time_frame>
    <description>Blood pressure will be measured two times for 48h during each intervention period; 48h before the baseline measurement and 5 days after baseline measurement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in average daytime diastolic blood pressure at 5 days</measure>
    <time_frame>48h ABPM before baseline visit and 5 days after baseline visit</time_frame>
    <description>Blood pressure will be measured two times for 48h during each intervention period; 48h before the baseline measurement and 5 days after baseline measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 48h systolic blood pressure at 5 days</measure>
    <time_frame>48h ABPM before baseline visit and 5 days after baseline visit</time_frame>
    <description>Blood pressure will be measured two times for 48h during each intervention period; 48h before the baseline measurement and 5 days after baseline measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 48h diastolic blood pressure at 5 days</measure>
    <time_frame>48h ABPM before baseline visit and 5 days after baseline visit</time_frame>
    <description>Blood pressure will be measured two times for 48h during each intervention period; 48h before the baseline measurement and 5 days after baseline measurement.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Blood Pressure</condition>
  <arm_group>
    <arm_group_label>1g NWT-03, then placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>7 days 1g NWT-03, followed by 7 days placebo, separated by a 5-day wash-out period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo, then 1g NWT-03</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>7 days placebo, followed by 7days 1g NWT-03, separated by a 5-day wash-out period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2g NWT-03, then placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>7 days 2g NWT-03, followed by 7 days placebo, separated by a 5-day wash-out period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo, then 2g NWT-03</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>7 days placebo, followed by 7days 2g NWT-03, separated by a 5-day wash-out period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5g NWT-03, then placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>7 days 5g NWT-03, followed by 7 days placebo, separated by a 5-day wash-out period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo, then 5g NWT-03</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>7 days 5g NWT-03, followed by 7 days placebo, separated by a 5-day wash-out period</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>NWT-03, an egg-white protein hydrolysate</intervention_name>
    <description>For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given</description>
    <arm_group_label>1g NWT-03, then placebo</arm_group_label>
    <arm_group_label>2g NWT-03, then placebo</arm_group_label>
    <arm_group_label>5g NWT-03, then placebo</arm_group_label>
    <arm_group_label>placebo, then 1g NWT-03</arm_group_label>
    <arm_group_label>placebo, then 2g NWT-03</arm_group_label>
    <arm_group_label>placebo, then 5g NWT-03</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A combination of sweetener + aroma, which was equal to the combination used in the intervention period was given as placebo comparator.</description>
    <arm_group_label>1g NWT-03, then placebo</arm_group_label>
    <arm_group_label>2g NWT-03, then placebo</arm_group_label>
    <arm_group_label>5g NWT-03, then placebo</arm_group_label>
    <arm_group_label>placebo, then 1g NWT-03</arm_group_label>
    <arm_group_label>placebo, then 2g NWT-03</arm_group_label>
    <arm_group_label>placebo, then 5g NWT-03</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be able to give written informed consent,&#xD;
&#xD;
          -  Be between 35 and 75 years of age,&#xD;
&#xD;
          -  Be in generally good health as determined by the investigator,&#xD;
&#xD;
          -  Smokers and non-smokers are eligible,&#xD;
&#xD;
          -  Have a stable body weight (&lt; 5% change) over the past 3-months,&#xD;
&#xD;
          -  Have a Body Mass Index (BMI) between 25 and 35 kg/m2,&#xD;
&#xD;
          -  Be: (a) Normotensive (Systolic Blood Pressure &lt;130 mmHg &amp; Diastolic Blood Pressure &lt;85&#xD;
             mmHg), (b) High normotensive (Systolic Blood Pressure 130-139 mmHg &amp; Diastolic Blood&#xD;
             Pressure 85-89 mmHg) or (c) Mild hypertensive (Systolic Blood Pressure 140-159 mmHg &amp;&#xD;
             Diastolic Blood Pressure 90-99 mmHg).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Are less than 35 and greater than 75 years of age,&#xD;
&#xD;
          -  Females are pregnant, lactating or wish to become pregnant during the study.&#xD;
&#xD;
          -  Are hypersensitive to any of the components of the test product,&#xD;
&#xD;
          -  Have a significant acute or chronic coexisting illness such as cardiovascular disease,&#xD;
             Chronic kidney disease (CKD), gastrointestinal disorder, endocrinological disorder,&#xD;
             immunological disorder, metabolic disease or any condition which contraindicates, in&#xD;
             the investigators judgement, entry to the study,&#xD;
&#xD;
          -  Having a condition or have taken a medication that the investigator believes would&#xD;
             interfere with the objectives of the study, pose a safety risk or confound the&#xD;
             interpretation of the study results; to include diuretics, blood pressure medication&#xD;
             and medication interfering with renin-angiotensin-aldosterone system (RAAS), such as&#xD;
             ACE-inhibitors, angiotensin receptor blockers, direct renin inhibitors or aldosterone&#xD;
             receptor inhibitor,&#xD;
&#xD;
          -  Are taking non-steroidal anti-inflammatory drugs (NSAIDs) within 2 weeks of baseline&#xD;
             visit or for the duration of the trial,&#xD;
&#xD;
          -  Suffer from diabetes mellitus, either type I and type II,&#xD;
&#xD;
          -  Consume more than the recommended alcohol guidelines i.e. &gt;21 alcohol units/week for&#xD;
             males and &gt;14 units/week for females,&#xD;
&#xD;
          -  History of illicit drug use,&#xD;
&#xD;
          -  Use of nasal decongestants and other over-the counter or herbal preparation within 2&#xD;
             weeks of baseline visit and for the duration of the trial,&#xD;
&#xD;
          -  Heavy intake of coffee (i.e. more that 4 cups daily) within 2 weeks of baseline visit&#xD;
             and for the duration of the trial,&#xD;
&#xD;
          -  Individuals who, in the opinion of the investigator, are considered to be poor&#xD;
             attendees or unlikely for any reason to be able to comply with the trial,&#xD;
&#xD;
          -  Subjects may not be receiving treatment involving experimental drugs,&#xD;
&#xD;
          -  If the subject has been in a recent experimental trial, these must have been completed&#xD;
             not less than 60 days prior to this study. An exception will be made where subjects&#xD;
             have participated in part 1 of the study,&#xD;
&#xD;
          -  Have a malignant disease or any concomitant end-stage organ disease,&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Eustace, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College Cork</affiliation>
  </overall_official>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>November 6, 2013</study_first_submitted>
  <study_first_submitted_qc>May 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2014</study_first_posted>
  <last_update_submitted>May 22, 2014</last_update_submitted>
  <last_update_submitted_qc>May 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

